<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Flexible sigmoidoscopy is a valid screening tool for the early detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Recently published long-term data from UKFSST, a randomized controlled trial, demonstrate a 33% reduction in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidence and a 43% decrease in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> mortality, with once-in-a-lifetime screening </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand, data from the NORCCAP trial with a similar protocol show no reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> incidence and only nonsignificant decrease in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mortality at 7 years </plain></SENT>
<SENT sid="3" pm="."><plain>At best, flexible sigmoidoscopy can detect only 70% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and <z:mpath ids='MPATH_491'>polyps</z:mpath> as it does not detect the 40% of proximal <z:hpo ids='HP_0002664'>neoplasms</z:hpo> which are not associated with a distal lesion </plain></SENT>
<SENT sid="4" pm="."><plain>The advantage of flexible sigmoidoscopy over other screening modalities lies in its safety profile, patient tolerance, and overall acceptance </plain></SENT>
<SENT sid="5" pm="."><plain>Its technical simplicity, short duration, and cost-effectiveness advance its applicability to mass screening programs </plain></SENT>
</text></document>